149 research outputs found
From local networks of SMEs to virtual districts?
Industrial districts as local networks of small and medium enterprises (SMEs) rooted their competitiveness in a mix of economic relationships and social ties. Recently, network technologies have promised gains of efficiency through a reduction in transaction costs and showed new commercial opportunities for small firms. Despite the morphological similarities between industrial districts and network technologies, a longitudinal analysis of ICT diffusion within Italian districts shows that the foreseen convergence between the district economic model and new technologies should not be taken for granted. The observed specific evolutionary paths concerning technology innovation in local systems also opens-up issues of economic policy
Actions fostering the adoption of Industry 4.0 technologies in manufacturing companies in European regions
Industry 4.0, a concept comprising a range of promising innovations enabled by the recent advancements in digital technologies, has become a priority of industrial policy in many European countries and regions. In this paper, we present actions undertaken by regional organisations (including the so-called Digital Innovation Hubs), fostering the adoption of Industry 4.0 technologies in manufacturing companies. Using examples from Germany, Italy and Poland, we show actions that enable the creation of general conditions for such implementations and help companies develop an individual strategy for adopting Industry 4.0 innovations
The Role of Meningioma-1 (Mn1) Gene as Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: A Concise Review
Molecular markers are necessary for prognostic stratification and monitoring of Minimal
Residual Disease (MRD) in Acute Myeloid Leukemia (AML) [1,2]. Cytogenetic aberrations have
long been recognized as the most important prognostic variable in AML, and are still the major
determinant for post-remission therapy [3]. Unfortunately, only 50-60% of AML patients present
an abnormal karyotype at diagnosis, while the remaining cases display a Normal Karyotype (NK).
NK AML patients are generally included in an “intermediate risk” prognostic group, that is however
characterized by a heterogeneous clinical course. To stratify prognosis of NK AML patients,
numerous studies have led, in the last decade, to the introduction of different molecular markers
such as FLT3, NPM1, BAALC and CEBPA [4-7]. Still, their use to monitor disease, either defining
remission status and detecting relapse as early as possible, is still somehow controversial, due to
fluctuations during disease course, low incidence rates in AML and sensitivity of the technologies
detecting the single marker [8-10]. These limitations have, to date, precluded a timely and precise
quantification of disease in NK AML patients, thus preventing from a complete individualization
of post-remission therapy and early treatment in case of impending relapse. In other words, in
NK AML it has not been reached the precision achieved in BCR/ABL-positive chronic myeloid
leukemia and PML/RAR alpha mutated acute promyelocytic leukemia
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia
The FMS-like tyrosine kinase 3 (FLT3) mutation in acute myeloid leukemia (AML) is a negative prognostic factor and, in these cases, allogeneic stem cell transplantation (allo-SCT) can represent an important therapeutic option, especially if performed in complete remission (CR). However, it is increasingly clear that not all cytological CRs (cCRs) are the same and that minimal residual disease (MRD) before allo-SCT could have an impact on AML outcome. Unfortunately, FLT3, due its instability of expression, is still not considered a good molecular MRD marker. We analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms\u2019 tumor (WT1) gene. Sixty-two consecutive AML FLT3-positive patients received allo-SCT between 2005 and 2016 in our center. The median age at transplantation was 55 years. The quantitative analysis of the WT1 gene expression (bone marrow samples) was available in 54 out of 62 (87%) cases, both at diagnosis (100% overexpressing WT1 with a mean of 9747 \ub1 8064 copies) and before allo-SCT (33 WT1-negative and 21 WT1-positive cases at the pretransplantation workup). Of these cases, 33/54 (61%) were both in cCR and molecular remission (WT1-negative) at the time of transplantation, 13/54 (24%) were in cCR but not in molecular remission (WT1-positive), and 8/54 (15%) showed a cytological evidence of disease (relapsed or refractory). Both post-allo-SCT overall survival (OS) and disease-free survival (DFS) were significantly better in patients who were WT1-negative (WT1 250 copies), with a median OS and DFS not reached in the WT1-negative group and 10.2 and 5.5 months, respectively, in the WT1-positive group (OS log\u2013rank p = 0.0005; hazard ratio [HR] = 3.7, 95% confidence interval [95% CI] = 1.5\u20139; DFS log\u2013rank p = 0.0001; HR = 4.38, 95% CI = 1.9\u201310). Patients with cCR who were WT1-positive had the same negative outcome as those with a cytological evidence of disease. The relapse rate after allo-SCT was 9% (3/33) in pre-allo-SCT WT1-negative cases and 54% (7/13) in WT1-positive cases (p = 0.002). At multivariate analysis, WT1 negativity before allo-SCT and grade <2 acute graft versus host disease were the only independent prognostic factors for improved OS and DFS. These data show that pre-allo-SCT molecular MRD evaluation through WT1 expression is a powerful predictor of posttransplantation outcomes (OS, DFS, relapse rate). Patients with both cCR and a WT1-negative marker before allo-SCT have a very good outcome with very low relapse rate; conversely, patients with positive molecular MRD and refractory/relapsed patients have a negative outcome. The WT1 MRD stratification in FLT3-positive AML is a valuable tool with which to identify patients who are at high risk of relapse and that could be considered from post-allo-SCT prophylaxis with FLT3 inhibitors or other strategies (donor lymphocyte infusion, tapering of immunosuppression, azacitidine). \ua9 2017 ISEH - International Society for Experimental Hematolog
Il distretto e le nuove tecnologie dell\u2019informazione e della comunicazione: situazione attuale e prospettive
- …